



FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON2		SERIAL NO.: 10/056,347	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald BURCH et al.			
				FILING DATE: January 25, 2002		GROUP: 1639	





U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL	AA	AB	AC	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS									
AD		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
								Yes	No

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
<div style="font-size: 2em; margin-bottom: 10px;">M</div> AE	Purdue Discovery Research, Department of Neuropharmacology Study Report "Assessment of the Effects of Combined Administration of Oxycodone and Cox II Inhibitors, Celecoxib, Etodolac and Rofecoxib, in the Rat FCA Model of Inflammatory Pain"; July 28, 2003
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	
AO	
AP	
AQ	
AR	
AS	

EXAMINER		DATE CONSIDERED
		11/7/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON2		SERIAL NO.: 10/056,347	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald BURCH et al.			
				FILING DATE: January 25, 2002		GROUP: 1639	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	AA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AH						
	AI						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AJ	The Merck Index, 12 th edition, Merck & Co. Publishers, p.1194 (1996)					
	AK	Goodman and Gillman's The Pharmacological Basis of Therapeutics, 6 th edition, Macmillan Publishing Co., "Chapter 22: Opioid Analgesics and Antagonists," p.494-497, esp. Tables 22-1, p. 496 (1980)					
	AL	Rorarius et al., "Non-steroidal Anti-inflammatory Drugs for Postoperative Pain Relief," Current Opinion in Anesthesiology, 7:358-362 (1994)					
	AM	Friedel et al., "Nabumetone- A Reappraisal of its Pharmacology and Therapeutics Use in Rheumatic Diseases," Drugs Vol. 45 (1):131-156, (1993)					
	AN	Eversmeyer et al., "Safety Experience With Nabumetone Versus Diclofenac, Naproxen, Ibuprofen, and Piroxicam in Osteoarthritis and Rheumatoid Arthritis, The American Journal of Medicine, Vol. 95 (Suppl. 2A) pp. 10S-18S					
	AO	Lipani, "Clinical Update of the Relative Safety of Nabumetone in Long-Term Clinical Trials," Inflammopharmacology (1995) Vol 3(4) pp. 351-361					
	AP	Tanaka et al., "Pharmacological Studies of the New Antiinflammatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one," Arzneim-Forsch./Drug res. 42 (II), Nr. 7, pp. 935-944 (1992)					
	AQ	Swingle et al., "Preclinical Pharmacological Studies With Nimesulide," Drugs Exptl. Clin. Res. Vol. X (8-9) pp. 587-597					
	AR	Rabasseda, "Nimesulide: A Selective Cyclooxygenase 2 Inhibitor Antiinflammatory Drug," Drugs of Today Vol 32, No.5 (1996), p9. 365-384					
	AS	Siebert et al., "Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 In Inflammation and Pain," PNAS USA Vol.91 (Dec. 1994) pages 12013-12-17					
	AT	Richardson et al., "The Clinical Implications of Inhibition of the Inducible Form of Cyclo-oxygenase," Drug Safety Vol. 15(4), pp. 249-260 (Oct. 1996)					
EXAMINER				DATE CONSIDERED			
							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							